<DOC>
	<DOCNO>NCT01899573</DOCNO>
	<brief_summary>The study design demonstrate safety , feasibility potential efficacy use AccuCinch® System reduce functional mitral regurgitation .</brief_summary>
	<brief_title>Percutaneous Left Ventricular Reshaping Reduce Functional Mitral Regurgitation Improve LV Function</brief_title>
	<detailed_description />
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Age &gt; 18 year Subjects clinically significant mitral regurgitation ( MR 2+ ) Ejection Fraction ≥ 25 % Stable cardiac medical regimen heart failure least 1 month Stable NYHA Classification least 1 month Subject eligible cardiac surgery The subject inform nature study , agree provision , provide write informed consent Myocardial infarction within 90 day intend treatment device Prior surgical , transcatheter , percutaneous mitral valve intervention Any intervention coronary artery disease ( CAD ) within last 30 day prior treatment , unrevascularized multivessel coronary disease Hemodynamic instability need emergent surgery Nonambulatory NYHA Class IV symptom heart failure subject require IV inotropic support Subjects sufficient quality echocardiography ( TTE TEE ) obtain Echocardiography evidence primary mitral valve disease cause MR MS , Evidence mitral valve stenosis estimate valve area le 3.0 cm2 Mitral valve prosthesis pathology would prevent adequate function GDS Accucinch System Estimated GFR &lt; 30ml/min/1.73m2 Greater mild mitral annular calcification observe fluoroscopy Presence aortic valve prosthesis Moderate severe aortic valve stenosis calcification observe echocardiography fluoroscopy Severe aortic arch calcification mobile aortic atheroma observe echocardiography fluoroscopy Active bacterial endocarditis History bleed diathesis coagulopathy History stroke within prior 6 month Subjects anticoagulation contraindicate Any clinical evidence investigator feel would place subject increase risk placement device . Concurrent medical condition life expectancy le 12 month Currently participate investigational study Comorbid condition place subject unacceptable surgical risk ( e.g . severe chronic obstructive pulmonary disease , hepatic failure , immunological abnormality , hematological abnormality ) Subjects indication concomitant surgery coronary artery bypass graft ( CABG ) , aortic valve reconstruction replacement , tricuspid repair replacement , leave ventricular remodel surgery congenital repair Any cardiac resynchronization therapy within last 3 month prior treatment Subjects high dose steroid immunosuppressant therapy Female subject pregnant , child bear potential lactating Subjects unable unwilling comply followup schedule requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>mitral regurgitation</keyword>
	<keyword>mitral valve</keyword>
</DOC>